The estimated Net Worth of Michael Castagna is at least $18.7 Milion dollars as of 27 August 2024. Mr. Castagna owns over 85,106 units of Mannkind Corp stock worth over $14,067,345 and over the last 8 years he sold MNKD stock worth over $3,124,496. In addition, he makes $1,551,760 as Chief Executive Officer a Director at Mannkind Corp.
Michael has made over 31 trades of the Mannkind Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 85,106 units of MNKD stock worth $536,168 on 27 August 2024.
The largest trade he's ever made was selling 200,482 units of Mannkind Corp stock on 14 December 2023 worth over $801,928. On average, Michael trades about 17,503 units every 57 days since 2016. As of 27 August 2024 he still owns at least 2,294,836 units of Mannkind Corp stock.
You can see the complete history of Mr. Castagna stock trades at the bottom of the page.
Dr. Michael E. Castagna Pharm.D. serves as Chief Executive Officer, Director of the Company. Mr. Castagna also served as a Corporate Vice President, Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined us, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Company (“BMS”). Before BMS, Mr. Castagna served as Vice President and Head, Biopharmaceuticals, North America, at Sandoz, a division of Novartis. Beginning in 1997, he held positions with commercial or medical affairs responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from the University of the Sciences-Philadelphia College of Pharmacy, a Pharm.D. from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. The Board believes that Mr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
As the Chief Executive Officer a Director of Mannkind Corp, the total compensation of Michael Castagna at Mannkind Corp is $1,551,760. There are no executives at Mannkind Corp getting paid more.
Michael Castagna is 43, he's been the Chief Executive Officer a Director of Mannkind Corp since 2017. There are 22 older and no younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.
Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens a David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Mannkind Corp executives and other stock owners filed with the SEC include: